In his fascinating and challenging article Dr Martinez (December 1994;49: 1189-91) suggests that viral infections occurring early in life may protect against atopy and asthma by driving T helper cells towards a predominantly Thl phenotype. We wonder whether viral infections of the mother during pregnancy may not also have a part to play in providing some temporary immunity to the infant with related consequences, and suggest that the hypothesis has parallels in mycobacterial disease which suggest a common therapeutic approach.
The relationship shown in many studies between maternal influenza and the subsequent development of schizophrenia in the offspring has never been easy to explain. ' Drs Agostini and Semenzato preface their discussion by stating that "despite pulmonary complications which are characteristic of advanced phases of HIV-1 infection, the lungs can be infected even in the asymptomatic phase." The authors refer to their previous review4 to substantiate this statement but, in a discussion ofasymptomatic infection during which four papers are quoted, three refer to studies in patients with AIDS and the fourth is a case report on two AIDS-related complex patients with lymphocytic interstitial pneumonitis. However, they have inexplicably ignored an important study regarding HIV-1 load and cytokine activity in the lung of asymptomatic HIV seropositive patients published by Rich and colleagues in January 1994.5 In relation to our own work they go on to suggest that our results are inconsistent -even incompatible -with findings that might be predicted in asymptomatic individuals. The reason for this is that all our published work to date comes from patients with established AIDS. Indeed, all individuals in our studies underwent bronchoscopy for diagnostic reasons. The authors incorrectly state that "HIV-1 can be more readily detected in the BAL fluid of individuals with Pneumocystis carinii pneumonia (PCP) than in patients with non-PCP lung infections .. ." What we have shown is that HIV-1 can be isolated by culture more readily from the cells in BAL fluid of individuals with PCP,6 a finding that has been subsequently substantiated by others.7 Next the authors state that "retroviral sequences are found more frequently in the lungs of individuals receiving no antiviral chemotherapy than in those receiving treatment with zidovudine (AZT) . . . " In fact we have shown by polymerase chain reaction (PCR) that HIV-1 DNA could be detected in the BAL cells of 65% of individuals on AZT compared with 64% of patients taking no antiviral chemotherapy. 8 We also showed that we could isolate HIV-1 in culture from the BAL cells of 52% of AIDS patients on AZT compared with 64% of individuals on no antiviral therapy, but the difference between the two groups was not statistically significant.68 Subsequent work by us using quantitative PCR methods has shown that there is a reduction in the quantity ofHIV proviral DNA/1 o6 BAL cells in AIDS patients on AZT compared with those not on antiviral therapy,9 and similar reductions have been observed by others for peripheral blood cells.'0 Letters to the editor The authors then state that "it has also been observed that HIV-1 detection in BAL fluid samples is significantly associated with progression to death but not to reduction of pulmonary function tests." Again our results were from patients with AIDS and the reason for the lack of correlation between these two parameters could be due to a masking by the concomitant opportunistic respiratory infection. It is well established that PCP has a profound effect on the carbon monoxide transfer factor (TLCO) in HIV-1 seropositive individuals." We reiterate that all our patients underwent bronchoscopy because they had a respiratory episode. It should be pointed out that in our study the mean TLCO value in patients was 46-3 regardless of whether HIV could or could not be cultured from the BAL cells of these individuals.'2 Conversely, direct damage to lung physiology by HIV-1 may occur during the asymptomatic phase, in which case any viral-associated reductions would have occurred in these patients prior to our investigations. Perhaps patients with AIDS should have undergone bronchoscopic examination before and in between respiratory episodes to determine what direct effect HIV-1 may be having on pulmonary function, but this was ethically unacceptable at the time of our studies.
Drs Agostini and Semenzato continue by stating that "detailed analyses are needed to characterise HIV-1 strains completing reverse transcription in the lung in vivo. These data are central to verifying whether the emergence of retroviral variants represents an important factor affecting the pulmonary manifestations of HIV-1 infection." We have already shown that the biological phenotypes isolated from BAL cells of patients with AIDS can be distinguished in all instances so far tested from the corresponding phenotype isolated from a matched peripheral blood sample.'3 Furthermore, the emergence of more virulent syncytium-inducing HIV-1 variants does occur in BAL cells of some individuals in the terminal stages of AIDS.'4 Genotypic characterisation of these strains is already underway.
They conclude their editorial by stating that "longitudinal studies of BAL fluid findings in a large number of HIV-1 infected patients followed from an asymptomatic stage until the diagnosis of AIDS are necessary to define clearly the natural course of the respiratory illness in HIV-1 infection. 
